| Autor: |
Haddad A; Lilly Research Laboratories, Eli Lilly and Company, Dubai, United Arab Emirates., Jabbour M; Division of Urology, Saint Georges Hospital, Balamand University, Achrafieh, Beirut, Lebanon., Bulbul M; Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon. |
| Jazyk: |
angličtina |
| Zdroj: |
Arab journal of urology [Arab J Urol] 2015 Sep; Vol. 13 (3), pp. 155-61. Date of Electronic Publication: 2015 Jul 10. |
| DOI: |
10.1016/j.aju.2015.06.004 |
| Abstrakt: |
Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting a link between ED and LUTS/BPH, and the results from key clinical studies related to the use of PDE5 inhibitors for treating both conditions. The results from these studies suggest that men who have both ED and LUTS/BPH, and are concerned about their sexual dysfunction, might benefit from single-agent, holistic treatment with a PDE5 inhibitor. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
